Pediatric Meropenem Dosing for ESBL-Producing Klebsiella pneumoniae
For pediatric patients with ESBL-producing Klebsiella pneumoniae infections, administer meropenem 20 mg/kg IV every 8 hours (maximum 1 gram per dose) for children ≥3 months of age, infused over 30 minutes to 3 hours. 1
Age-Specific Dosing
Children ≥3 Months of Age with Normal Renal Function
- Standard dose: 20 mg/kg IV every 8 hours (maximum 1 gram per dose) 1
- Administration: Infuse over 15-30 minutes, or as a bolus over 3-5 minutes for doses up to 1 gram 1
- For children >50 kg: Administer 1 gram IV every 8 hours 1
Infants <3 Months of Age with Normal Renal Function
The dosing is based on gestational age (GA) and postnatal age (PNA): 1
- Infants <32 weeks GA and PNA <2 weeks: 20 mg/kg every 12 hours
- Infants <32 weeks GA and PNA ≥2 weeks: 20 mg/kg every 8 hours
- Infants ≥32 weeks GA and PNA <2 weeks: 20 mg/kg every 8 hours
- Infants ≥32 weeks GA and PNA ≥2 weeks: 30 mg/kg every 8 hours
- Administration: Infuse over 30 minutes 1
Optimizing Pharmacodynamic Target Attainment
Extended infusion strategies significantly improve outcomes against ESBL-producing organisms. For bacteria with higher minimum inhibitory concentrations (MIC ≥2 μg/mL), which is common with ESBL-producing K. pneumoniae, consider: 2
- 40 mg/kg IV every 8 hours (maximum 2 grams per dose) with 4-hour infusion achieves 97% probability of target attainment (50% time above MIC) 2
- Standard 0.5-hour infusion at 40 mg/kg achieves only 60.7% probability of target attainment for MIC ≥2 μg/mL 2
For severe infections or documented high MIC organisms, use 40 mg/kg every 6 hours infused over 3 hours, which successfully achieved 100% time above MIC for >40% of the dosing interval in a pediatric case of KPC-producing K. pneumoniae bacteremia 3
Renal Impairment Adjustments
No pediatric-specific data exist for renal impairment dosing. 1 For adult guidance that may inform pediatric decisions in consultation with nephrology: 1
- CrCl 26-50 mL/min: Standard dose every 12 hours
- CrCl 10-25 mL/min: Half dose every 12 hours
- CrCl <10 mL/min: Half dose every 24 hours
Clinical Considerations
Meropenem demonstrates excellent efficacy against ESBL-producing K. pneumoniae with clinical success rates of 93-96% in pediatric populations. 4, 5 The drug maintains 100% susceptibility against ESBL producers, including those with high-level resistance to other β-lactams 6
Monitor for neutropenia and eosinophilia, which occur more frequently than previously reported, though meropenem remains generally well-tolerated 5
Duration of therapy: Typically 10-14 days for bacteremia, though this should be guided by clinical response and source control 3, 5
Critical Pitfalls to Avoid
- Do not use standard 0.5-hour infusions for organisms with MIC ≥2 μg/mL - this results in inadequate pharmacodynamic target attainment and risks treatment failure 2
- Do not underdose based on weight - children >50 kg should receive full adult doses (1 gram every 8 hours), not weight-based dosing capped at lower amounts 1
- Do not delay therapy pending susceptibility results - meropenem provides reliable empiric coverage for ESBL-producing K. pneumoniae while awaiting culture data 4, 6